About the Journal

Download [This article belongs to Volume - 64, Issue - 03]

Abstract : Citrus peel is a worthy bioactive compound source to develop. This research aims to (1) extract and analyze secondary metabolites in essential oils (EO) of Citrus sinensis peel (a), Citrus nobilis peel (b), Citrus reticulata L. peel (c), and Citrus maxima [Burm]. peel (d) using GCMS, (2) separate and analyze secondary metabolites in the fractions of each EO, (3) observe the anti-inflammatory of each EO by bovine albumin denaturation method, (4) analyze all secondary metabolites by in silico anti-inflammatory and drug-likeness. In this current project, the EO(a) and EO(b) were extracted using hydrodistillation, while the EO(c) and EO(d) were extracted via the hydro-steam distillation method. The research results show that EO(a), EO(b), EO(c), and EO(d) were 0.42%, 0.57%, 0.50% and 0.35%, respectively. Each EO that has been obtained was fractionated at four boiling point levels 80-90 °C, 90-95 °C, 150-160 °C and above 160 °C. The GCMS analysis showed that (d/l)-limonene was the main compound in EO(a) 44.10 %, EO(b) 42.25 %, EO(c) 31.75 %, and EO(d) 46.03%. The fraction of (c-1) contains the highest limonene (96.26%). Anti-inflammatory tests revealed IC50 of 0.5545 mg/ml (a), 1.0049 mg/ml (b), 0.7509 mg/ml (c), and 2.8229 mg/ml (d). In silico analysis shows trans-β-caryophyllene and valencene have the optimum complex binding energy with the 6QS9 and 2BXE. Drug-likeness observations show that all secondary metabolites are safe orally consumed. This finding complements scientific information on citrus peel as an anti-inflammatory and preliminary research for drug development from bioactive natural resources.